1. Home
  2. ARDC vs NGEN Comparison

ARDC vs NGEN Comparison

Compare ARDC & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Dynamic Credit Allocation Fund Inc.

ARDC

Ares Dynamic Credit Allocation Fund Inc.

HOLD

Current Price

$11.99

Market Cap

311.3M

Sector

Finance

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$4.25

Market Cap

337.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARDC
NGEN
Founded
N/A
2017
Country
United States
Canada
Employees
N/A
14
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
311.3M
337.4M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
ARDC
NGEN
Price
$11.99
$4.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
127.0K
130.8K
Earning Date
01-01-0001
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.52
$3.51
52 Week High
$15.03
$5.93

Technical Indicators

Market Signals
Indicator
ARDC
NGEN
Relative Strength Index (RSI) 36.82 56.39
Support Level N/A $3.65
Resistance Level $13.55 $4.44
Average True Range (ATR) 0.17 0.23
MACD 0.03 0.06
Stochastic Oscillator 47.50 84.27

Price Performance

Historical Comparison
ARDC
NGEN

About ARDC Ares Dynamic Credit Allocation Fund Inc.

Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: